Papers
List our Papers
The promise of anti-ErbB3 monoclonals as new cancer therapeutics.
Aurisicchio L, Marra E, Roscilli G, Mancini R, Ciliberto G. Oncotarget. 2012 Aug;3(8):744-58. Review.
Genetic cancer vaccines: current status and perspectives.
Aurisicchio L, Ciliberto G. Expert Opin Biol Ther. 2012 Aug;12(8):1043-58. doi: 10.1517/14712598.2012.689279. Epub 2012 May 12. Review.
Monoclonal antibody-induced ErbB3 receptor internalization and degradation inhibits growth and migration of human melanoma cells.
Belleudi F, Marra E, Mazzetta F, Fattore L, Giovagnoli MR, Mancini R, Aurisicchio L, Torrisi MR, Ciliberto G. Cell Cycle. 2012 Apr 1;11(7):1455-67. doi: 10.4161/cc.19861. Epub 2012 Apr 1.
Novel anti-ErbB3 monoclonal antibodies show therapeutic efficacy in xenografted and spontaneous mouse tumors.
Aurisicchio L, Marra E, Luberto L, Carlomosti F, De Vitis C, Noto A, Gunes Z, Roscilli G, Mesiti G, Mancini R, Alimandi M, Ciliberto G. J Cell Physiol. 2012 Oct;227(10):3381-8. doi: 10.1002/jcp.24037.
Spheres derived from lung adenocarcinoma pleural effusions: molecular characterization and tumor engraftment.
Mancini R, Giarnieri E, De Vitis C, Malanga D, Roscilli G, Noto A, Marra E, Laudanna C, Zoppoli P, De Luca P, Affuso A, Ruco L, Di Napoli A, Mesiti G, Aurisicchio L, Ricci A, Mariotta S, Pisani L, Andreetti C, Viglietto G, Rendina EA, Giovagnoli MR, Ciliberto G. PLoS One. 2011;6(7):e21320. doi: 10.1371/journal.pone.0021320. Epub 2011 Jul 18.